Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BLS PharmaceuticalsASX:BLS 46 Cash Ratio is 0.74 as of Dec. 2025, which is 66% below its 10-year median of 2.18. GuruFocus rates ASX:BLS with a GF Score™ of 46/100 and a GF Value™ of A$0.69 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,386 Biotechnology companies, BLS Pharmaceuticals ranks worse than 78.21% on this metric.
BLS Pharmaceuticals has a Cash Ratio of 0.74. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for BLS Pharmaceuticals's Cash Ratio or its related term are showing as below:
ASX:BLS'
s Cash Ratio Range Over the Past 10 Years
Min: 0.35 Med: 2.18 Max: 6.49
Current: 0.74
During the past 13 years, BLS Pharmaceuticals's highest Cash Ratio was 6.49. The lowest was 0.35. And the median was 2.18.
ASX:BLS's Cash Ratio is ranked worse than 78.21% of 1386
companies
in the Biotechnology industry
Industry Median: 2.93
vs ASX:BLS: 0.74
BLS Pharmaceuticals (ASX:BLS) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
BLS Pharmaceuticals Cash Ratio Related Terms
BLS Pharmaceuticals Cash Ratio Historical Data
* Premium members only.
The historical data trend for BLS Pharmaceuticals's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BLS Pharmaceuticals's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BLS Pharmaceuticals Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BLS Pharmaceuticals's Cash Ratio distribution charts can be found below:
* The bar in red indicates where BLS Pharmaceuticals's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BLS Pharmaceuticals (ASX:BLS) has a Cash Ratio of 0.74 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on BLS Pharmaceuticals and its competitors. This is 66% below median its historical median of 2.18. Over the past decade, BLS Pharmaceuticals' Cash Ratio has ranged from 0.35 to 6.49. According to the industry distribution chart, BLS Pharmaceuticals ranks #1084 out of 1386 companies in the Biotechnology industry, placing it in the top 78.2%.
Is BLS Pharmaceuticals' Cash Ratio too high?
BLS Pharmaceuticals' current Cash Ratio of 0.74 is 66% below median its 10-year median of 2.18. Over the past 10 years, this metric has ranged from a low of 0.35 to a high of 6.49. The Biotechnology industry median Cash Ratio is 2.93. BLS Pharmaceuticals' value of 0.74 is 74.7% below this industry median. Based on the distribution chart, BLS Pharmaceuticals ranks #1084 out of 1386 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BLS Pharmaceuticals has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BLS Pharmaceuticals' Cash Ratio compare to KHC and GIS?
According to the Biotechnology industry distribution chart, BLS Pharmaceuticals ranks #1084 out of 1386 companies for Cash Ratio. This places BLS Pharmaceuticals in the lower half of its industry. The industry median Cash Ratio is 2.93. BLS Pharmaceuticals' value of 0.74 is 74.7% below this benchmark. Historically, BLS Pharmaceuticals' own Cash Ratio has ranged from 0.35 to 6.49 over the past decade. While the company's 10-year median is 2.18 vs. the industry median of 2.93, BLS Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.93, based on 1,386 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BLS Pharmaceuticals's current Cash Ratio of 0.74 is 74.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on BLS Pharmaceuticals and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BLS Pharmaceuticals's current Cash Ratio is 0.74, which is 66% below median its own 10-year median of 2.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BLS Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, BLS Pharmaceuticals (ASX:BLS) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.69, compared to a current price of A$0.97 — trading 40.6% above its estimated fair value. The current Cash Ratio is 0.74, which is 66% below median its 10-year median of 2.18 and 74.7% below the Biotechnology industry median of 2.93. BLS Pharmaceuticals' overall GF Score™ is 46/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For BLS Pharmaceuticals (ASX:BLS), the current Cash Ratio is 0.74 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BLS Pharmaceuticals (ASX:BLS) Overvalued in 2026?
Based on GuruFocus' analysis, BLS Pharmaceuticals stock appears to be overvalued.
The current stock price of A$0.97 is trading 40.6% above its estimated GF Value™ of A$0.69.
GuruFocus considers BLS Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for ASX:BLS:
Cash Ratio: 0.74 (66% below median its 10-year median of 2.18)
GF Value™: A$0.69 vs. price of A$0.97 (40.6% above fair value)
Industry Position: 74.7% below the Biotechnology median (#1084 of 1386)
No single metric tells the full story. See the ASX:BLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioxyne Ltd is an Australian life science and health products company. The company is engaged in the development, manufacture, and distribution of consumer dietary supplements based on the proprietary probiotic strain of Lactobacillus fermentum PCC. Some of its products include Breathe Life Science, Dr Watson, BLS Clinics, Mirai Solution, CanXChange, and others. The company operates in segments, namely, Pharmaceutical manufacture and wholesale supply (business to business), Manufacture and distribution (wholesale, online, and retail), and Wholesale of patented Probiotics.
46GF Score
Get the complete analysis for ASX:BLS
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BLS has been successfully added to your 
